Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG1 | P05089 | 1/20 | 0.50 |
| ▸ | OTC | P00480 | 1/20 | 0.44 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.39 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.39 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.39 |
| ▸ | GRIK4 | Q16099 | 1/20 | 0.39 |
| ▸ | GRIK5 | Q16478 | 1/20 | 0.39 |
| ▸ | TGM2 | P21980 | 1/20 | 0.36 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.36 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.35 |
| ▸ | LDHA | P00338 | 1/20 | 0.35 |
| ▸ | LDHB | P07195 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2363512 | 1.00 | ARG1 (0.50) | ARG1OTCSMYD3NAMPTGRIK1 | |
| SCHEMBL2363931 | 0.92 | ARG1 (0.46) | ARG1OTCSMYD3NAMPTGRIK1 | |
| SCHEMBL2363934 | 0.92 | ARG1 (0.46) | ARG1OTCSMYD3NAMPTGRIK1 | |
| SCHEMBL13585082 | 0.84 | GRIN3B (0.45) | ARG1SMYD3NAMPTGRIK1GRIK2 | |
| SCHEMBL2363842 | 0.84 | GRIN3B (0.45) | ARG1SMYD3NAMPTGRIK1GRIK2 | |
| SCHEMBL15208292 | 0.77 | ARG1 (0.50) | ARG1OTCGRIK1GRIK2GRIK3 | |
| SCHEMBL15208293 | 0.77 | ARG1 (0.50) | ARG1OTCGRIK1GRIK2GRIK3 | |
| SCHEMBL15208859 | 0.75 | NPC1 (0.58) | OTC | |
| SCHEMBL15208864 | 0.75 | NPC1 (0.58) | OTC | |
| SCHEMBL15208779 | 0.74 | OTC (0.44) | ARG1OTCTGM2DDAH1EGLN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9637520-B2 | Template-fixed peptidomimetics with CXCR7 modulating activity | POLYPHOR AG (CH) | 2017-05-02 | — | — | US | disclosed |
| EP-2531520-B1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CXCR7 MODULATING ACTIVITY | POLYPHOR AG (CH) | 2016-05-11 | — | — | EP | disclosed |
| US-20150307556-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CXCR7 MODULATING ACTIVITY | POLYPHOR AG (CH) | 2015-10-29 | — | — | US | disclosed |
| US-9109009-B2 | Template-fixed peptidomimetics with CXCR7 modulating activity | POLYPHOR AG (CH) | 2015-08-18 | — | — | US | disclosed |
| US-20130225506-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CXCR7 MODULATING ACTIVITY | POLYPHOR AG (CH) | 2013-08-29 | — | — | US | disclosed |
| EP-2531520-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CXCR7 MODULATING ACTIVITY | Polyphor AG (CH) | 2012-12-12 | — | — | EP | disclosed |
| WO-2011095607-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CXCR7 MODULATING ACTIVITY | POLYPHOR AG (CH) | 2011-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307556-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CXCR7 MODULATING ACTIVITY | CXCR1, CXCL12, CXCR6 | ARG1 889/4885OTC 3226/4885SMYD3 3216/4885 |
| US-20130225506-A1 | TEMPLATE-FIXED PEPTIDOMIMETICS WITH CXCR7 MODULATING ACTIVITY | CXCR1, CXCL12, CXCR6 | ARG1 971/4885OTC 3134/4885SMYD3 3243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.